The Cleveland Clinic Foundation
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1921-01-01
- Employees
- 1K
- Market Cap
- -
Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)
Phase 4
Completed
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2006-02-09
- Last Posted Date
- 2007-01-31
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 200
- Registration Number
- NCT00289042
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2015-04-06
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT00286156
- Locations
- 🇺🇸
The Cleveland Clinic- main campus, Cleveland, Ohio, United States
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant
Completed
- Conditions
- Psychosocial Effects of Cancer and Its TreatmentLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative DiseasesChronic Myeloproliferative DisordersLeukemia
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 36
- Registration Number
- NCT00281814
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
Phase 1
Completed
- Conditions
- MelanomaSarcomaUnspecified Adult Solid Tumor, Protocol SpecificMultiple MyelomaLymphomaBreast CancerKidney Cancer
- Interventions
- Biological: recombinant interferon alpha-1bDrug: IFN
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 35
- Registration Number
- NCT00276536
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
Phase 2
Completed
- Conditions
- LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT00274781
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL
Not Applicable
Completed
- Conditions
- Lymphoma
- Interventions
- Biological: filgrastimBiological: rituximab
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2011-03-29
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 55
- Registration Number
- NCT00274794
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2
Completed
- Conditions
- Leukemia
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT00274807
FIRE-PAD: Functional Improvement Through Revascularization of the Extremities for Peripheral Arterial Disease
Terminated
- Conditions
- Peripheral Vascular Disease
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2008-06-27
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 37
- Registration Number
- NCT00274157
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
The Effects of Hypercapnia, Supplemental Oxygen, and Dexamethasone on Surgical Wound Infection
Phase 3
Completed
- Conditions
- Surgical Wound InfectionSurgery, Colon
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 2000
- Registration Number
- NCT00273377
- Locations
- 🇮🇪
Mater Misericordiae Hospital, Dublin, Ireland
🇺🇸Outcomes Research Institute, Louisville, Kentucky, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Lymphoma, B-Cell
- Interventions
- Other: external beam radiotherapy plus 90-Y ibritumomab tiuxetan
- First Posted Date
- 2005-12-29
- Last Posted Date
- 2010-12-21
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 12
- Registration Number
- NCT00271050
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath